Acrivon moves oral CDK11 inhibitor toward IND filing in early 2027
Acrivon Therapeutics announced that its oral CDK11 inhibitor, ACR‑7280, has progressed to IND‑enabling studies. The company plans to submit an IND application to the FDA in the first half of 2027, initially targeting acute myeloid leukemia. Preclinical work showed the drug caused complete tumor regression in AML xenograft models and displayed synergy with other agents.
Why it matters
The IND timeline sets the earliest possible start of human trials, which could shape Acrivon's pipeline and future revenue prospects, according to the company’s press release. Investors will watch the outcome of the IND filing as a milestone for a potential new AML therapy.
Key facts
- 1Acrivon named ACR‑7280, an oral CDK11 inhibitor, its next development candidate. tradingview.com
- 2The company intends to file an IND with the FDA in the first half of 2027. tradingview.com
- 3Preclinical studies reported complete tumor regression in AML xenograft models. tradingview.com
- 4Initial development will focus on AML, both as monotherapy and in combination regimens. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.